LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the conference on Tuesday, Jan. 10, at 3:00 p.m. PST.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
CONTACT:
KYTHERA Biopharmaceuticals, Inc.
Investor Contact:
Heather Rowe, 818-587-4559
[email protected]
or
Media Contact:
Erica Bazerkanian, 805-300-9289
[email protected]
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Research Science
MEDIA:
| Logo |